VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. Our CNS pipeline includes three drug candidates (AV-101, PH10, and PH94B) with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety. Each CNS drug candidate in our pipeline is either currently in or has completed Phase 2 clinical development. AV-101, an oral NMDA receptor glycine site antagonist (a full antagonist), is in Phase 2 development in the U.S. for major depressive disorder (MDD) and in a first-step target engagement study in healthy volunteer U.S. military Veterans for suicidal ideation. The FDA has granted Fast Track designation for development of AV-101, both as a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain. PH10 is a potential first-in-class neuroactive nasal spray with rapid-onset antidepressant effects observed at microgram doses and without systemic exposure. PH10 is in Phase 2 development for MDD. PH94B is a potential first-in-class neuroactive nasal spray with rapid-onset effects observed at microgram doses and without systemic exposure. Phase 2 and pilot Phase 3 development of PH94B for Social Anxiety Disorder (SAD) has been completed successfully, and PH94B is now being prepared for pivotal Phase 3 development as an on-demand PRN treatment for SAD. VistaStem Therapeutics is VistaGen's wholly owned subsidiary focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.
View Top Employees from VistaGen Therapeutics, Inc.Website | http://www.vistagen.com |
Ticker | VTGN |
Revenue | $1 million |
Funding | $150000 |
Employees | 40 (40 on RocketReach) |
Founded | 1998 |
Address | 343 Allerton Ave, South San Francisco, California 94080, US |
Phone | (650) 577-3600 |
Fax | (888) 482-2602 |
Technologies |
JavaScript,
HTML,
PHP
+27 more
(view full list)
|
Industry | Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Clinical Trials, Health Care, Pharmaceutical |
Web Rank | 2 Million |
Keywords | Vistagen, Av101, Vistagen Therapeutics, Vistagen William Blair, Av在线看101 |
Competitors | AGY Therapeutics, Inc., Affectis Pharmaceuticals, Axsome Therapeutics, Inc., NeurOp, Inc., Visterra Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 55 Companies, NAICS Code 325 Companies |
Looking for a particular VistaGen Therapeutics, Inc. employee's phone or email?
The VistaGen Therapeutics, Inc. annual revenue was $1 million in 2023.
Joanne Curley is the Independent Board Member of VistaGen Therapeutics, Inc..
40 people are employed at VistaGen Therapeutics, Inc..
VistaGen Therapeutics, Inc. is based in South San Francisco, California.
The NAICS codes for VistaGen Therapeutics, Inc. are [32, 3254, 55, 325].
The SIC codes for VistaGen Therapeutics, Inc. are [28, 283].